BIBF 1120 (Nintedanib) is a potent, ATP-competitive VEGFR, FGFR, and PDGFR inhibitor. It affects VEGF, FGF, and PDGF signaling, by binding to the kinase ATP-binding clefts, inhibiting angiogenesis, tumor growth, and pulmonary fibrosis.
BIBF 1120 (Nintedanib) IC50 for Cell-based and Cell-free Assays
Comprehensive IC50 Values for BIBF 1120 (Nintedanib) Across Cell-free Enzyme Inhibitory Profiles and Cell-based Functional Assays.